<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="9464">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 09, 2023</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05697237</url>
  </required_header>
  <id_info>
    <org_study_id>XJTU1AF2021LSK-368</org_study_id>
    <nct_id>NCT05697237</nct_id>
  </id_info>
  <brief_title>Carlizumab Plus Sovantinib in Second-line Treatment of Advanced or Metastatic Cholangiocarcinoma</brief_title>
  <official_title>Exploratory Clinical Study of Carlizumab Plus Sovantinib in Second-line Treatment of Advanced or Metastatic Cholangiocarcinoma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>First Affiliated Hospital Xi'an Jiaotong University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>First Affiliated Hospital Xi'an Jiaotong University</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The incidence of cholangiocarcinoma is high, the radical resection rate is low, the&#xD;
      postoperative recurrence is easy, the prognosis is poor.Gemcitabine combined with cisplatin&#xD;
      (GC) is the standard first-line treatment for patients with advanced biliary carcinoma, and&#xD;
      up to now there is no standard second-line treatment Commend.Carrilizumab was highly&#xD;
      effective in previous studies,Its combined GEMOX protocol has been published in the&#xD;
      &quot;Guidelines for the Diagnosis and Treatment of Gallbladder Cancer (2019 Edition)&quot; and the&#xD;
      &quot;China Clinical Oncology&quot; The Society's (CSCO) Guidelines for the Diagnosis and Treatment of&#xD;
      Biliary alignancies 2020 is recommended for the first-line treatment of advanced biliary&#xD;
      cancers.Solfantinib is targeted at VEGFR1, 2, 3, FGFR1And CSF1R highly selective small&#xD;
      molecule targeted therapy drugs. Data from a preliminary phase 2 clinical trial observed&#xD;
      sofantinib therapy Survival benefits of cholangiocarcinoma patients in China.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      In this study, carrilizumab combined with suvantinib in the second-line treatment of patients&#xD;
      with advanced or metastatic cholangiocarcinoma with single arm, open, Exploratory clinical&#xD;
      trials. The study plan enlists 60 patients with unresectable or recurrent disease confirmed&#xD;
      by histopathology or cytology Or metastatic cholangiocarcinoma (including intrahepatic&#xD;
      cholangiocarcinoma, extrahepatic cholangiocarcinoma, distal cholangiocarcinoma). Past&#xD;
      acceptance of standard containing Systematic internal medicine anti-tumor therapy with&#xD;
      gemcitabine regimen met the inclusion criteria of this study, and carrilizumab combined with&#xD;
      cord was given Vantinib oral therapy. The specific treatment regimen was carrilizumab 200mg&#xD;
      Q3W d1; Solventinib: 300mg, Orally, once a day, continuously. Treatment continues or until&#xD;
      disease progression occurs or the patient becomes intolerant to the treatment regimen The&#xD;
      efficacy was evaluated every 2 cycles. The main evaluation of carrilizumab combined with&#xD;
      suvantinib in second-line treatment was advanced or Progression-free survival (PFS) in&#xD;
      patients with metastatic cholangiocarcinoma.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">January 2023</start_date>
  <completion_date type="Anticipated">December 2024</completion_date>
  <primary_completion_date type="Anticipated">June 2024</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>PFS</measure>
    <time_frame>6months</time_frame>
    <description>Progression Free Survival</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>ORR</measure>
    <time_frame>6months</time_frame>
    <description>Objective Response Rate</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>OS</measure>
    <time_frame>12months</time_frame>
    <description>Overall Survival</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>DCR</measure>
    <time_frame>6months</time_frame>
    <description>Disease control rate Disease control rate Disease control rate</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">60</enrollment>
  <condition>Cholangiocarcinoma</condition>
  <arm_group>
    <arm_group_label>Advanced or metastatic cholangiocarcinoma</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>In this study, carrilizumab combined with sovantinib in the second-line treatment of patients with advanced or metastatic cholangiocarcinoma with single arm, open, Exploratory clinical trials.The specific treatment regimen was carrilizumab 200mg Q3W d1; Sofantinib: 300mg,Take orally, once a day, continuously. Treatment continues or until disease progression occurs or the patient becomes intolerant to treatment regimens.The efficacy was evaluated every 2 cycles.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Carrelizumab</intervention_name>
    <description>Carrelizumab 200mg/3 weeks</description>
    <arm_group_label>Advanced or metastatic cholangiocarcinoma</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Solfantinib</intervention_name>
    <description>Solfantinib 300mg/d</description>
    <arm_group_label>Advanced or metastatic cholangiocarcinoma</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Advanced inability to root was pathologically confirmed Patients with curatively&#xD;
             resected or metastatic bile duct epithelial cell carcinoma;&#xD;
&#xD;
          2. had previously received systemic antitumor therapy with a chemotherapy regimen&#xD;
             (including gemcitabine)&#xD;
&#xD;
          3. Age ≥18 and under 75&#xD;
&#xD;
          4. Predicted survival ≥3 months&#xD;
&#xD;
          5. ECOG score 0-1&#xD;
&#xD;
          6. Child-Pugh score &lt; 8&#xD;
&#xD;
          7. There was at least one measurable tumor lesion with a long diameter ≥10 mm and a short&#xD;
             diameter ≥15 mm on spiral CT，For general CT or physical examination, the maximum&#xD;
             diameter must be ≥20mm&#xD;
&#xD;
          8. The results of liver and kidney function and blood routine examination within 1 week&#xD;
             before enrollment were consistent with the following&#xD;
             conditions：ANC≥1.5×10^9/L,PLT≥80×10^9/L,HGB≥80g/L,Cr≤1.5×ULN,TBIL≤2.5×ULN,ALP≤2.5×ULN,&#xD;
             AST≤2.5×ULN,ALT≤2.5×ULN&#xD;
&#xD;
          9. Patients participate voluntarily and sign informed consent forms&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Known allergies to carrilizumab or solfantinib machine components&#xD;
&#xD;
          2. Patients with obstructive jaundice who could not reach the upper limit of TBIL≤2.5&#xD;
             times of normal value after surgical intervention&#xD;
&#xD;
          3. Patients with biliary obstruction that may occur or worsen within 4 to 6 weeks&#xD;
&#xD;
          4. Patients with obvious coagulation mechanism disorder, active bleeding and bleeding&#xD;
             tendency&#xD;
&#xD;
          5. History of other malignancies within 5 years (fully treated basal cell carcinoma of&#xD;
             the skin, cervical cancer in situ)&#xD;
&#xD;
          6. Interstitial pneumonia or pulmonary fibrosis&#xD;
&#xD;
          7. Uncontrollable pleural effusion or ascites&#xD;
&#xD;
          8. Severe uncontrolled medical disease, acute infection, recent history of myocardial&#xD;
             infarction (within 3 months)&#xD;
&#xD;
          9. Pregnant or lactating mothers who refused to take appropriate contraceptive measures&#xD;
             during the course of the study;&#xD;
&#xD;
         10. The researchers determined that the patients were not suitable for this study&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>enxiao li, PHD</last_name>
    <role>Principal Investigator</role>
    <affiliation>First hospital of Xi'an Jiaotong University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>yangwei fan, phd</last_name>
    <phone>+8615029078171</phone>
    <email>1159950306@qq.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>rui qu</last_name>
    <phone>+18681943306</phone>
    <email>1289271841@qq.com</email>
  </overall_contact_backup>
  <verification_date>December 2022</verification_date>
  <study_first_submitted>December 21, 2022</study_first_submitted>
  <study_first_submitted_qc>January 16, 2023</study_first_submitted_qc>
  <study_first_posted type="Actual">January 25, 2023</study_first_posted>
  <last_update_submitted>January 16, 2023</last_update_submitted>
  <last_update_submitted_qc>January 16, 2023</last_update_submitted_qc>
  <last_update_posted type="Actual">January 25, 2023</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cholangiocarcinoma</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

